sepantronium
Small moleculeexperimental
Clinical trial activity
12 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
11
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2005 (NCT00281541)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Burkitt Lymphoma · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Genes, myc · Phase 2
- Lung Neoplasms · Phase 2
- Lymphatic Diseases · Phase 2
- Lymphoma, B-Cell · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Melanoma · Phase 2
- Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms · Phase 2
Mechanism of action
BIRC5 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COCC[n+]1c2c(n(Cc3cnccn3)c1C)C(=O)c1ccccc1C2=O- Mol. weight
- 363.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2110734 ↗
- ChEMBLCHEMBL2105734 ↗
Also known as
- 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1h-naphtho(2,3-d)imidazolium
- 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1h-naphtho(2,3-d)imidazolium bromide
- sepantronium
- sepantronium
- sepantronium bromide
- sepantronium bromide
- sepantronium bromide
- ym155
- ym155
- ym 155
- ym-155
- ym-155
- ym-155
- ym155 cpd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05263583 | Phase 2 | Dec 9, 2022 | Cothera Bioscience, Inc |
| NCT01100931 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2010 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT01038804 | Phase 2 | Dec 1, 2009 | Astellas, Free University of Brussels, The Royal Bournemouth Hospital, Thomayer's Hospital, University of Duesseldorf |
| NCT01007292 | Phase 2 | Nov 1, 2009 | Astellas |
| NCT01009775 | Phase 2 | Nov 1, 2009 | Astellas |
| NCT01023386 | Phase 1 | Nov 1, 2009 | Astellas |
| NCT00498914 | Phase 2 | Jun 1, 2007 | Astellas |
| NCT00514267 | Phase 1/Phase 2 (Phase 2) | May 1, 2007 | Astellas |
| NCT00328588 | Phase 2 | Dec 1, 2006 | Astellas |
| NCT00818480 | Phase 2 | Feb 1, 2006 | Astellas |
| NCT00257478 | Phase 2 | Nov 22, 2005 | Astellas |
| NCT00281541 | Phase 2 | Nov 1, 2005 | Astellas |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astellas | For profit | 10 | 10 | 2 | 2005 |
| Cothera Bioscience, Inc | For profit | 1 | 1 | 1 | 2022 |
| Free University of Brussels | Academic/Hospital | 1 | 0 | 1 | 2009 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2010 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2010 |
| The Royal Bournemouth Hospital | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Thomayer's Hospital | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Duesseldorf | Academic/Hospital | 1 | 0 | 1 | 2009 |
8 organizations
Page 1 / 1